Immune Cell Therapy for H3K27M-Positive Brain Tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a personalized immune cell therapy for people with a specific type of brain tumor (DIPG or midline glioma) that has the H3K27M mutation. The treatment uses your own immune cells, which are modified to find and attack the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of brain tumor called diffuse midline glioma or DIPG that has come back or is not responding to treatment.
- Your tumor has a specific genetic change called H3K27M.
- You are between 2 and 70 years old.
- You are generally able to care for yourself (Karnofsky score 60 or higher).
- You have not had a certain type of chemotherapy wafer (Gliadel) within the last month, and you are not currently taking antibody therapies.
- You do not have HIV, active tuberculosis, or an autoimmune disease that needs long-term steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine made from immune cells (dendritic cells) designed to train your body to fight brain tumors like DIPG or glioblastoma. You may qualify if you have one of these tumors, have had standard treatment, and are generally healthy enough for the study.
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial tests a new treatment using special immune cells called Vγ9Vδ2 T cells, given directly into the brain fluid. It is for people with a very aggressive grade 4 brain tumor (malignant glioma) that has not gotten better with standard treatments.
Hear when a new Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.